Transcriptomics

Dataset Information

0

RNAseq of rhabdomyosarcoma cells after treatment with SGI-110 and/or Dasatinib


ABSTRACT: Patients with metastatic or recurrent rhabdomyosarcoma, the most common childhood soft tissue sarcoma, continue to do poorly and new treatments are needed. In this study we evaluated a novel combination therapy using a dna methyltransferase inhibitor, SGI-110, and the SRC family kinase inhibitor, Dasatinib. To understand the transcriptional changes that occur after treatment with SGI-110 with and without Dasatinib we performed RNAseq on two human RMS cell lines (Rh30 and RD) after 5 days of drug treatment.

ORGANISM(S): Homo sapiens

PROVIDER: GSE147240 | GEO | 2021/04/30

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2021-04-30 | GSE147246 | GEO
2020-12-19 | GSE163468 | GEO
2018-06-26 | GSE105065 | GEO
| PRJNA613485 | ENA
2014-10-02 | E-GEOD-55613 | biostudies-arrayexpress
2014-10-02 | GSE55613 | GEO
2019-10-03 | GSE138322 | GEO
| 2148118 | ecrin-mdr-crc
| 2153426 | ecrin-mdr-crc
2016-12-01 | E-MTAB-5321 | biostudies-arrayexpress